The Benefits

To Patients:
The Cardiovascular Innovation Institute will give patients access to the newest generation of bio-adaptive heart innovations that augment or replace the functioning capacity of failing hearts and can save the lives of terminally ill heart-failure patients. Patients will also benefit by participating in the newest FDA-approved clinical trials and thus have first access to life-saving technology. Moreover, patients in Kentucky will have access to highly trained cardiac surgeons who have the surgical experience (high number of implantations) and team readiness that smaller centers cannot offer.

To the Commonwealth of Kentucky:
The creation of the Cardiovascular Innovation Institute will further the reputation of Kentucky as a leader in the development, testing, improvement and clinical evaluation of bio-adaptive heart innovations. The institute will provide University of Louisville researchers with the support and infrastructure needed to capture more extramural funding from the federal government and industry. For every $1 million in federal grants the University of Louisville receives, $2.5 million is added to the local economy. The institute will also help fuel the new economy of Kentucky by establishing new business relationships in Louisville, attracting medical device companies to Louisville and developing start-up biomedical companies in Louisville.

To the University of Louisville (U of L):
University of Louisville faculty members will become more competitive for federal research grants based on new knowledge discovered at the institute. This effort can make a major contribution to U of L President James Ramsey’s goals of substantially increasing the level of funded research. The institute’s facilities and reputation will also enable UofL to recruit a larger cadre of federally funded medical, veterinary and engineering faculty.

To Jewish Hospital:
The creation of the Cardiovascular Innovation Institute will further strengthen the medical partnership between Jewish Hospital and the University of Louisville School of Medicine. The institute will increase the hospital’s access to new research and clinical trials for the benefit of patients and for the enhanced regional and national reputation of Jewish Hospital as a heart and lung center of excellence. This, in turn, will create an expanded regional referral stream of new patients to the hospital.